What's new? Log in Free sign up

Novo Nordisk A/S (NVO)

Company Profile

Company profile

Ticker

NVO, NONOF

Exchange

Website

www.novonordisk.com

CEO

Mr. Lars Fruergaard Jorgensen

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

BEXY COMMUNICATIONS INC, CHENIERE ENERGY INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NVO stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Current report (foreign)

Disclosure regarding Iran Threat Reduction and Syria Human Rights Act

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Annual report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Financial summary

Financial statements Chart NVO financial data

Quarter (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

NVO institutional ownership history Ownership history

7.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1622	1771	-8.4%
Opened positions	192	149	+28.9%
Closed positions	341	226	+50.9%
Increased positions	583	693	-15.9%
Reduced positions	633	641	-1.2%

13F shares	Current	Prev Q	Change
Total value	26.44 tn	36.09 tn	-26.7%
Total shares	336.94 mm	334.59 mm	+0.7%
Total puts	10.51 mm	7.78 mm	+35.2%
Total calls	11.35 mm	4.94 mm	+129.9%
Total put/call ratio	0.9	1.6	-41.2%

Largest owners	Shares	Value	Change
Jennison Associates	19.94 mm	$1.72 tn	-1.2%
BAC Bank of America	15.49 mm	$1.33 tn	+8.1%
GQG Partners	12.99 mm	$1.12 tn	+74.7%
Fisher Asset Management	12.64 mm	$1.09 tn	-5.0%
MS Morgan Stanley	12.20 mm	$1.05 tn	-15.0%
Loomis Sayles & Co L P	11.57 mm	$995.40 mm	+34.2%
Fayez Sarofim & Co	11.38 mm	$979.29 bn	-6.8%
FMR	10.02 mm	$862.08 bn	-44.1%
Folketrygdfondet	8.90 mm	$765.92 bn	+0.5%
Renaissance Technologies	8.31 mm	$715.08 bn	+1.5%

Largest transactions	Shares	Bought/sold	Change
FMR	10.02 mm	-7.91 mm	-44.1%
GQG Partners	12.99 mm	+5.56 mm	+74.7%
RJF Raymond James Financial	4.71 mm	+4.71 mm	NEW
Raymond James & Associates	0.00	-3.53 mm	EXIT
T. Rowe Price	6.35 mm	-3.24 mm	-33.8%
Loomis Sayles & Co L P	11.57 mm	+2.95 mm	+34.2%
Nuveen Asset Management	6.24 mm	+2.64 mm	+73.2%
MS Morgan Stanley	12.20 mm	-2.16 mm	-15.0%
Two Sigma Investments	1.84 mm	+1.84 mm	NEW
International Assets Investment Management	19.91 k	-1.79 mm	-98.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

6 Stocks to Buy as European Markets Soar

Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug.

Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs

President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs.

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity

Press releases

From Benzinga Pro

ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

NEW YORK, March 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and December 19, 2024,

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm,

Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug - Hagens Berman

SAN FRANCISCO, Feb. 28, 2025 /PRNewswire/ -- Novo Nordisk A/S (NYSE:NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obesity treatment,

March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO

Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.